Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease

Journal of Hypertension

Volumn 24, Issue SUPPL. 1, 2006, Pages

  Weinberg, Adam J ^a   Zappe, Dion H ^b   Ramadugu, Rajeev ^b   Weinberg, Marc S ^b,c,d  

^a Boston University   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Angiotensin II type 1 receptor blockers; Blood pressure; Chronic kidney disease; Hyperkalemia; Hypertension; Proteinuria; Renin angiotensin system; Serum creatinine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN; VASODILATOR AGENT; CREATININE; POTASSIUM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; LONG TERM CARE; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECT; KIDNEY DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; POTASSIUM;

EID: 33745524927     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220413.22482.36     Document Type: Article

References (19)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310:356-360.
2. De Jong PE, de Zeeuw D, Navis G. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354:352-353.
3. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria preducts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27:2033-2039.
4. Weir MR. Reduction in microalbuminuria: a biomeasure of therapeutic success? Hypertension 2005; 45:181-182.
5. Weinberg MS, Weinberg AJ, Zappe DH. Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2000; 1:217-233.
6. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhary Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
7. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension study. Hypertension 2005; 45:198-202.
8. Weinberg MS, Weinberg AJ, Cord R, Zappe D. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst 2001; 1 (suppl 1):196-198.
9. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68:1190-1198.
10. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 2003; 5:418-425.
11. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004; 24:340-345.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1-S266.
13. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
14. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999; 100:1056-1064.
15. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
16. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16:3038-3045.
17. Aranda P, Aranda FJ, Frutos MA, Lopez de Novales E, Aranda PJ, Ruilope LM. Long-term renoprotective effects of usual versus high dose of telmisartan in non-diabetic nephropathies [Abstract]. Am J Hypertens 2004; 17:148.
18. Muirhead N, Burgess E, de Cotret PR, for the SMART Investigators. A randomised controlled trial of high dose candesartan in the treatment of proteinuric renal disease: design and baseline characteristics. SMART Study. J Am Soc Nephrol 2005; 16:SA-PO261.
19. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799-812.